Skip to main content

Table 1 Demographics of the 238 cisplatin-treated TCSs

From: Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study

Age at diagnosis, years Median (range)

29.3 (14.6 – 63.6)

Observation time, months Median (range)

11.8 (4.3 – 19.3)

Age at survey, years Median (range)

42.3 (22.7 – 73.4)

Histology, number (%)

Seminoma: 44 (18.5%)

Non-seminoma: 194 (81.5%)

Stage according to Royal Marsden Hospital, number of patients (%)

I: 72 (30.2%, incl. 2 IM)

 

II: 101 (42.4%)

 

III: 13 (5.5%)

 

IV: 52 (21.8%)

Number of cycles of chemotherapy

1–3: 52 (21.8%)

4: 141 (59.2%)

5–7: 34 (14.3%)

>8: 11 (4.6%)

First Regimen (n = 238)

Completed by 100% of TCSs

BEP: 104 (43.7%), CVB: 104 (43.7%), BOPVIP: 10 (4.2%), Others: 20 (8.4%)

Second Regimen (n = 44)

Completed by 18.5% of TCSs

BEP: 17 (39%), VIP: 12 (27%), EP: 5 (11%), Others: 10 (23%)

Third regimen (n = 8)

VIP: 2, EP: 2, Others: 4

Fourth Regimen (n = 1)

EP: 1

Number of TCSs exposed to the most common cytotoxic agents and cumulative doses among those [mg/m2], median (range)

Cisplatin (n = 238) : 397 (81 – 1571)

Bleomycin (n = 226) : 145 (29–212)

Vinblastine (n = 105) : 35 (10–51)

Etoposide (n = 146) : 1434 (41–4934)